0.73
+0.009(+1.26%)
Currency In USD
| Previous Close | 0.72 |
| Open | 1.08 |
| Day High | 1.12 |
| Day Low | 0.69 |
| 52-Week High | 9.55 |
| 52-Week Low | 0.67 |
| Volume | 100.19M |
| Average Volume | 342,070 |
| Market Cap | 11.16M |
| PE | 1.42 |
| EPS | 0.51 |
| Moving Average 50 Days | 1.07 |
| Moving Average 200 Days | 1.82 |
| Change | 0.01 |
SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
GlobeNewswire Inc.
3 hours ago
Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the fi
SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet
GlobeNewswire Inc.
Oct 08, 2025 1:00 PM GMT
COMMACK, NY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through
SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
GlobeNewswire Inc.
Oct 01, 2025 1:00 PM GMT
Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunit